论文部分内容阅读
目的：观察大于75岁的高龄心房颤动（房颤）患者围导管消融期三种抗凝方案的安全有效性。方法选取2011年7月到2013年12月行房颤导管消融治疗的高龄（＞75岁）房颤患者85例，术前常规华法林抗凝后经食管超声检查排除左心耳血栓，分为三组：传统抗凝组30例，消融前停用华法林，以低分子肝素桥接，术中用普通肝素抗凝，术后桥接低分子肝素联合华法林过渡到单用华法林；华法林持续使用组32例，围消融期正常使用华法林，术中使用普通肝素抗凝；新型口服抗凝药物组23例（达比加群组12例，利伐沙班组11例），术前、术中同传统抗凝组，术后4h开始服用达比加群或利伐沙班抗凝。比较三组抗凝方案围术期到术后3个月的出血和栓塞事件发生率及其他并发症。结果传统抗凝组住院期间新发脑梗死1例，下肢血肿7例，假性动脉瘤1例，出院后3个月内内脏出血1例，小出血事件6例；华法林持续使用组院内下肢血肿4例，出院后3个月内小出血事件4例；新型口服抗凝药物院内下肢血肿2例，出院后无小出血事件。结论高龄房颤患者行导管消融治疗，总体安全有效。与传统抗凝治疗方案对比，持续使用华法林方案或采用新型口服抗凝药物能进一步降低出血并发症风险，并未增加血栓栓塞的风险。“,”Objective To observe the safety and efficacy of different periprocedural anticoagulation strategies in patients undergoing catheter ablation of atrial ifbrillation. Methods Eighty-five patients aged over 75 undergoing catheter ablation of atrial fibrillation from Jul 2011 to Nov 2013 were enrolled. They all took warfarin and transesophageal echocardiograms were performed to rule out left atrium appendage thrombus before ablation. They were divided into 3 groups. In Group 1 (30 cases), warfarin was stopped and bridged with low molecular weight heparin (LMWH) 3 days before procedure and LMWH bridging followed by warfarin alone after procedure. In Group 2 (32 cases), warfarin was continued during periprocedural period. In Group 3 (23 cases), Dabigatran or Rivaroxaban alone was used 4 hours after procedure respectively. Unfractionated heparin was used during procedure in all three groups. These three anticoagulation strategies were compared in bleeding, embolism events and other complications during 3-month follow-up. Results In Group 1, there were 1 new-onset ischemic stroke during hospitalization, 7 lower extremity hematomas, 1 subdural hemorrhage during 3-month follow-upand 6 minor bleeding events. In Group 2, there were 4 lower extremity hematomas and 4 minor bleeding events during 3-month follow-up. As for Group 3, only 2 lower extremity hematomas during hospitalization was observed in each without any minor bleeding events during follow-up. Conclusions Catheter ablation in elderly atrial ifbrillation patients was safe and effective in general. Compared with traditional anticoagulation strategy, continuing warfarin or novel oral anticoagulants could reduce bleeding complications without increasing thromboembolism risk.